110 results on '"Rönnelid, Johan"'
Search Results
2. Exhaled Nitric Oxide Reflects the Immune Reactions of the Airways in Early Rheumatoid Arthritis.
- Author
-
Weitoft, Tomas, Rönnelid, Johan, Lind, Anders, de Vries, Charlotte, Larsson, Anders, Potempa, Barbara, Potempa, Jan, Kastbom, Alf, Martinsson, Klara, Lundberg, Karin, and Högman, Marieann
- Subjects
NITRIC oxide ,RHEUMATOID factor ,PEPTIDES ,C-reactive protein ,PORPHYROMONAS gingivalis ,RHEUMATOID arthritis - Abstract
Patients with rheumatoid arthritis (RA) have altered levels of exhaled nitric oxide (NO) compared with healthy controls. Here, we investigated whether the clinical features of and immunological factors in RA pathogenesis could be linked to the NO lung dynamics in early disease. A total of 44 patients with early RA and anti-citrullinated peptide antibodies (ACPAs), specified as cyclic citrullinated peptide 2 (CCP2), were included. Their exhaled NO levels were measured, and the alveolar concentration, the airway compartment diffusing capacity and the airway wall concentration of NO were estimated using the Högman–Meriläinen algorithm. The disease activity was measured using the Disease Activity Score for 28 joints. Serum samples were analysed for anti-CCP2, rheumatoid factor, free secretory component, secretory component containing ACPAs, antibodies against Porphyromonas gingivalis (Rgp) and total levels of IgA, IgA1 and IgA2. Significant negative correlations were found between the airway wall concentration of NO and the number of swollen joints (Rho −0.48, p = 0.004), between the airway wall concentration of NO and IgA rheumatoid factor (Rho −0.41, p = 0.017), between the alveolar concentration and free secretory component (Rho −0.35, p = 0.023) and between the alveolar concentration and C-reactive protein (Rho −0.36, p = 0.016), but none were found for anti-CCP2, IgM rheumatoid factor or the anti-Rgp levels. In conclusion, altered NO levels, particularly its production in the airway walls, may have a role in the pathogenesis of ACPA-positive RA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation.
- Author
-
Pertsinidou, Eleftheria, Saevarsdottir, Saedis, Manivel, Vivek Anand, Klareskog, Lars, Alfredsson, Lars, Mathsson-Alm, Linda, Hansson, Monika, Cornillet, Martin, Serre, Guy, Holmdahl, Rikard, Skriner, Karl, Jakobsson, Per-Johan, Westerlind, Helga, Askling, Johan, and Rönnelid, Johan
- Published
- 2024
- Full Text
- View/download PDF
4. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis—an exploratory study.
- Author
-
Hamberg, Viggo, Sohrabian, Azita, Volkmann, Elizabeth R., Wildt, Marie, Löfdahl, Anna, Wuttge, Dirk M., Hesselstrand, Roger, Dellgren, Göran, Westergren-Thorsson, Gunilla, Rönnelid, Johan, and Andréasson, Kristofer
- Published
- 2023
- Full Text
- View/download PDF
5. The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis.
- Author
-
Westerlind, Helga, Kastbom, Alf, Rönnelid, Johan, Hansson, Monika, Alfredsson, Lars, Mathsson-Alm, Linda, Serre, Guy, Cornillet, Martin, Holmdahl, Rikard, Skriner, Karl, Bang, Holger, Klareskog, Lars, Saevarsdottir, Saedis, Lundberg, Karin, Grönwall, Caroline, and Askling, Johan
- Subjects
THROMBOEMBOLISM risk factors ,PROTEIN metabolism ,CARDIOVASCULAR diseases risk factors ,AUTOANTIBODIES ,VEINS ,CONFIDENCE intervals ,IMMUNOGLOBULINS ,HLA-B27 antigen ,RISK assessment ,COMPARATIVE studies ,RHEUMATOID arthritis ,FIBRINOGEN ,THROMBOEMBOLISM ,DESCRIPTIVE statistics ,RESEARCH funding ,LONGITUDINAL method ,PROPORTIONAL hazards models ,DISEASE complications - Abstract
Objectives To assess the association between venous thromboembolic (VTE) events and autoantibodies, following patients from RA diagnosis, measuring occurrence, levels and collective load of different autoantibodies against post-translational protein modifications, in particular recognizing citrullination (e.g. citrullinated fibrinogen) and RF by isotype. Methods A cohort of 2814 patients with newly diagnosed RA were followed for incident VTE through register linkages. Sera from RA diagnosis were centrally analysed for antibodies to second generation cyclic citrullinated peptides (anti-CCP2), 20 anti-citrullinated protein antibody (ACPA) fine-specificities, antibodies to additional protein modifications (carbamylation and acetylation) and RF by isotype. Association between baseline serology status and future VTE was analysed using Cox regression adjusted for age, sex and calendar period of RA diagnosis, overall and stratified by anti-CCP2 and RF positivity. Results During a median 16 years of follow-up, 213 first-ever VTE events were registered (5.0/1000 person-years). IgG anti-CCP2 (present in 65% of cohort) associated with VTE (hazard ratio [HR] = 1.33, 95% CI: 1.00, 1.78), in a dose-response manner. The risk of VTE increased with number of ACPA fine-specificities. IgM RF, but no other RF isotypes, associated with VTE (HR = 1.38, 95% CI: 1.04, 1.82). The associations were independent from smoking and HLA-DRB1 shared epitope alleles. None of the carbamylated or acetylated antibody reactivities associated with VTE. Conclusion Anti-CCP2, load of ACPA fine-specificities and IgM RF at RA diagnosis are associated with an increased risk of future VTE in RA. Antibodies to citrullinated fibrinogen did not differ substantially from other ACPA fine-specificities. Autoreactivity to other post-translational modifications was not associated with VTE risk. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE.
- Author
-
Elbagir, Sahwa, Diaz-Gallo, Lina-Marcela, Grosso, Giorgia, Zickert, Agneta, Gunnarsson, Iva, Mahler, Michael, Svenungsson, Elisabet, and Rönnelid, Johan
- Subjects
THROMBOSIS risk factors ,THROMBOSIS prevention ,AUTOANTIBODIES ,THROMBOSIS ,CARDIOVASCULAR diseases risk factors ,STATISTICS ,TRIGLYCERIDES ,HLA-B27 antigen ,ANTIPHOSPHOLIPID syndrome ,MULTIVARIATE analysis ,PROTHROMBIN ,ALLELES ,RISK assessment ,COMPARATIVE studies ,RESEARCH funding ,DESCRIPTIVE statistics ,PHOSPHOLIPIDS ,SYSTEMIC lupus erythematosus ,ODDS ratio ,HIGH density lipoproteins ,LIPIDS ,DISEASE risk factors - Abstract
Objectives Emerging evidence demonstrates that aPS-PT associate with thrombotic events. Genetic predisposition, including HLA-DRB1 alleles, is known to contribute to the occurrence of conventional aPL [anti-β
2 glycoprotein-I (anti-β2 GPI) and aCL]. We investigated associations between aPS-PT and HLA-DRB1 * alleles and thrombosis in SLE. Conventional aPL were included for comparison. Methods We included 341 consecutive SLE patients, with information on general cardiovascular risk factors, including blood lipids, LA and thrombotic events. aPS/PT, anti-β2 GPI and aCL of IgA/G/M isotypes and LA were quantified. Results aPS/PT antibodies associated positively with HLA-DRB1 *13 [odds ratio (OR) 2.7, P = 0.002], whereas anti-β2 GPI and aCL antibodies associated primarily with HLA-DRB1*04 (OR 2.5, P = 0.0005). These associations remained after adjustment for age, gender and other HLA-DRB1 * alleles. HLA-DRB1*13 , but not DRB1*04 , remained as an independent risk factor for thrombosis and APS after adjustment for aPL and cardiovascular risk factors. The association between DRB1*13 and thrombosis was mediated by aPS-PT positivity. HLA-DRB1*03 , on the other hand, associated negatively with thrombotic events as well as all aPL using both uni- and multivariate analyses. HLA-DRB1*03 had a thrombo-protective effect in aPL-positive patients. Additionally, HLA-DRB1*03 was associated with a favourable lipid profile regarding high-density lipoprotein and triglycerides. Conclusions HLA-DRB1*13 confers risk for both aPS-PT and thrombotic events in lupus. The association between HLA-DRB1*13 and thrombosis is largely, but not totally, mediated through aPS-PT. HLA-DRB1*03 was negatively associated with aPL and positively with favourable lipid levels. Thus, HLA-DRB1*03 seems to identify a subgroup of SLE patients with reduced vascular risk. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
7. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
- Author
-
Selickaja, Sandra, Galindo-Feria, Angeles S, Dani, Lara, Mimori, Tsuneyo, Rönnelid, Johan, Holmqvist, Marie, Lundberg, Ingrid E, and Venalis, Paulius
- Subjects
TUMOR risk factors ,TUMOR diagnosis ,AUTOANTIBODIES ,NUCLEOTIDE separation ,REPORTING of diseases ,DERMATOMYOSITIS ,PREDICTIVE tests ,PRECIPITIN tests ,IMMUNOBLOTTING ,RISK assessment ,COMPARATIVE studies ,ENZYME-linked immunosorbent assay ,DESCRIPTIVE statistics ,SENSITIVITY & specificity (Statistics) ,DISEASE complications - Abstract
Objectives Anti‐TIF1-gamma autoantibodies can be detected with immunoprecipitation (IP), line blot (LB) and ELISA. We compared assay performance in patients with DM and the potential of these assays to detect anti-TIF1-gamma positive cancer-associated DM (CADM). Methods We included sera from 131 patients with DM followed at Karolinska University Hospital, Stockholm, Sweden and 82 healthy controls. Serum samples taken at DM diagnosis were tested for anti-TIF1-gamma autoantibodies with IP, two ELISAs (in-house and commercial) and LB. Cancer diagnosis and dates were obtained from the Swedish national cancer register. CADM was defined as a malignancy that developed within 3 years of DM diagnosis. Results Anti-TIF1-gamma autoantibodies were detected in 19/101 (18.8%), 15/113 (13.2%), 34/131 (26%) and 45/131 (34.4%) of the patients with IP, LB, in-house and commercial ELISA, respectively. The anti-TIF1-gamma results from the in-house ELISA were confirmed with IP in 93 of 101 (92%) cases, κ = 0.76, with a commercial ELISA in 110 of 131 (84%) cases, κ = 0.63, and with LB in 101 of 113 (89.3%) cases, κ = 0.67. Anti-TIF1-gamma results with IP were confirmed with LB in 85 of 92 (92.4%) cases, κ = 0.73. For detecting CADM, the anti-TIF1-gamma in-house ELISA had a sensitivity of 58% and specificity of 86%, the commercial ELISA had a sensitivity of 63% and specificity of 82%, IP had a sensitivity of 52% and specificity of 92%, LB had a sensitivity of 40% and specificity of 96%. Conclusion The two anti-TIF1-gamma ELISA assays had advantages both for autoantibody detection and to identify anti-TIF1-gamma-positive CADM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Anti-citrullinated protein antibody specificities and pulmonary fibrosis in relation to genetic loci in early rheumatoid arthritis.
- Author
-
Brink, Mikael, Ljung, Lotta, Hansson, Monika, Rönnelid, Johan, Holmdahl, Rickard, Skriner, Karl, Serre, Guy, Klareskog, Lars, and Rantapää-Dahlqvist, Solbritt
- Subjects
AUTOANTIBODIES ,RESEARCH ,CONFIDENCE intervals ,GENETIC testing ,RISK assessment ,RHEUMATOID arthritis ,GENOTYPES ,DESCRIPTIVE statistics ,RESEARCH funding ,PULMONARY fibrosis ,DATA analysis software ,LOGISTIC regression analysis ,DISEASE risk factors ,DISEASE complications - Abstract
Objectives Pulmonary manifestations in RA are common comorbidities, but the underlying mechanisms are largely unknown. The added value of a multiplex of ACPA and genetic risk markers was evaluated for the development of pulmonary fibrosis (PF) in an inception cohort. Methods A total of 1184 patients with early RA were consecutively included and followed prospectively from the index date until death or 31 December 2016. The presence of 21 ACPA fine specificities was analysed using a custom-made microarray chip (Thermo Fisher Scientific, Uppsala, Sweden). Three SNPs, previously found related to PF were evaluated, rs2609255 (FAM13A), rs111521887 (TOLLIP) and rs35705950 (MUC5B). ACPA and genetic data were available for 841 RA patients, of whom 50 developed radiologically defined PF. Results In unadjusted analyses, 11 ACPA specificities were associated with PF development. In multiple variable analyses, six ACPA specificities were associated with increased risk of PF: vimentin (Vim)60–75, fibrinogen (Fib)β62–78 (72), Fibα621–635, Bla26, collagen (C)II359–369 and F4-CIT-R (P < 0.01 to P < 0.05). The number of ACPA specificities was also related to PF development (P < 0.05 crude and adjusted models). In multiple variable models respectively adjusted for each of the SNPs, the number of ACPA specificities (P < 0.05 in all models), anti-Vim60–75 (P < 0.05, in all models), anti-Fibβ62–78 (72) (P < 0.001 to P < 0.05), anti-CII359–369 (P < 0.05 in all models) and anti-F4-CIT-R AQ4 (P < 0.01 to P < 0.05), anti-Fibα621–635 (P < 0.05 in one) and anti-Bla26 (P < 0.05 in two) were significantly associated with PF development. Conclusion The development of PF in an inception cohort of RA patients was associated with both presence of certain ACPA and the number of ACPA specificities and risk genes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Autoantibodies Associated with Autoimmune Liver Diseases in a Healthy Population: Evaluation of a Commercial Immunoblot Test.
- Author
-
Ahmad, Awais, Dahle, Charlotte, Rönnelid, Johan, Sjöwall, Christopher, and Kechagias, Stergios
- Subjects
CHOLANGITIS ,AUTOIMMUNE diseases ,AUTOANTIBODIES ,LIVER diseases ,AUTOIMMUNE hepatitis ,LIVER function tests - Abstract
Autoantibodies constitute important tools for diagnosing the autoimmune liver diseases (AILD) autoimmune hepatitis and primary biliary cholangitis. The EUROLINE immunoblot assay, detecting multiple specificities, is widely used, but the clinical importance of weakly positive findings is unclear. The manufacturer's recommended cut-off was evaluated by investigating AILD-associated autoantibodies in 825 blood donors and 60 confirmed AILD cases. Positive findings were followed up with immunofluorescence microscopy on rat tissue, anti-M2-ELISA, alternative immunoblot assay, and liver function tests. Thirty-six (4.4%) blood donors were positive with EUROLINE. The most common specificities were LC-1 (1.6%), gp210 (1.3%), and AMA-M2 (1.1%). In general, the positive results were higher in patients than in blood donors, whereas anti-LC-1 was higher in blood donors. The liver function tests were slightly elevated in 2 of the 36 immunoblot positive blood donors. The majority of the positive EUROLINE findings could not be confirmed with the follow-up tests. The EUROLINE-Autoimmune Liver Diseases-(IgG) immunoblot detected autoantibodies in 4.4% of blood donors without signs of AILD. Our findings indicate that the recommended cut-off can be raised for most specificities without loss of diagnostic sensitivity. The prevalence of anti-LC-1 among blood donors indicates a problem with the antigen source. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Associations of C-reactive protein isoforms with systemic lupus erythematosus phenotypes and disease activity.
- Author
-
Karlsson, Jesper, Wetterö, Jonas, Weiner, Maria, Rönnelid, Johan, Fernandez-Botran, Rafael, and Sjöwall, Christopher
- Published
- 2022
- Full Text
- View/download PDF
11. Extramucosal Formation and Prognostic Value of Secretory Antibodies in Rheumatoid Arthritis.
- Author
-
Martinsson, Klara, Kling, Lovisa Lyttbacka, Roos‐Ljungberg, Karin, Griazeva, Irina, Samoylovich, Marina, Paul, Stephane, Rönnelid, Johan, Weitoft, Tomas, Wetterö, Jonas, and Kastbom, Alf
- Subjects
AUTOANTIBODIES ,BIOMARKERS ,IMMUNOGLOBULINS ,RHEUMATOID arthritis - Abstract
Objective: To investigate levels and possible extramucosal formation of secretory Ig, including anti–citrullinated protein antibodies (ACPAs), in rheumatoid arthritis (RA). Methods: Three patient groups were studied: 1) ACPA‐positive patients with musculoskeletal pain without clinical arthritis, 2) patients with recent‐onset RA, and 3) patients with established RA. In baseline serum samples (groups 1 and 2) and paired synovial fluid samples (group 3), we analyzed total secretory IgA, total secretory IgM, free secretory component (SC), and SC‐containing ACPA. Extramucosal formation of SC‐containing ACPA was investigated by preincubating RA sera and affinity‐purified ACPA with recombinant free SC. Results: Compared to healthy controls, serum levels of total secretory IgA and total secretory IgM were increased both in patients with early RA and at‐risk patients (P < 0.05). Patients with early RA with elevated total secretory Ig had significantly higher disease activity during the 3‐year follow‐up period compared to those without increased levels. At‐risk patients who developed arthritis during follow‐up (39 of 82) had higher baseline total secretory IgA levels compared to those who did not (P = 0.041). In established RA, total secretory IgA and total secretory IgM levels were higher in serum than in synovial fluid (P < 0.0001), but SC‐containing ACPAs adjusted for total secretory Ig concentration were higher in synovial fluid (P < 0.0001). Preincubation with recombinant free SC yielded increased SC‐containing ACPA reactivity in sera as well as in affinity‐purified IgA and IgM ACPA preparations. Conclusion: Circulating secretory Ig are elevated before and at RA onset. In the presence of free SC, secretory Ig may form outside the mucosa, and SC‐containing ACPAs are enriched in RA joints. These findings shed important new light on the mucosal connection in RA development. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Antibodies to a Citrullinated Porphyromonas gingivalis Epitope Are Increased in Early Rheumatoid Arthritis, and Can Be Produced by Gingival Tissue B Cells: Implications for a Bacterial Origin in RA Etiology.
- Author
-
Sherina, Natalia, de Vries, Charlotte, Kharlamova, Nastya, Sippl, Natalie, Jiang, Xia, Brynedal, Boel, Kindstedt, Elin, Hansson, Monika, Mathsson-Alm, Linda, Israelsson, Lena, Stålesen, Ragnhild, Saevarsdottir, Saedis, Holmdahl, Rikard, Hensvold, Aase, Johannsen, Gunnar, Eriksson, Kaja, Sallusto, Federica, Catrina, Anca I., Rönnelid, Johan, and Grönwall, Caroline
- Subjects
B cells ,BACTERIAL cells ,PORPHYROMONAS gingivalis ,IMMUNOLOGIC memory ,SYNOVIAL fluid ,PERIODONTITIS ,RHEUMATOID arthritis ,PAIN threshold - Abstract
Based on the epidemiological link between periodontitis and rheumatoid arthritis (RA), and the unique feature of the periodontal bacterium Porphyromonas gingivalis to citrullinate proteins, it has been suggested that production of anti-citrullinated protein antibodies (ACPA), which are present in a majority of RA patients, may be triggered in the gum mucosa. To address this hypothesis, we investigated the antibody response to a citrullinated P. gingivalis peptide in relation to the autoimmune ACPA response in early RA, and examined citrulline-reactivity in monoclonal antibodies derived from human gingival B cells. Antibodies to a citrullinated peptide derived from P. gingivalis (denoted CPP3) and human citrullinated peptides were analyzed by multiplex array in 2,807 RA patients and 372 controls; associations with RA risk factors and clinical features were examined. B cells from inflamed gingival tissue were single-cell sorted, and immunoglobulin (Ig) genes were amplified, sequenced, cloned and expressed (n=63) as recombinant monoclonal antibodies, and assayed for citrulline-reactivities by enzyme-linked immunosorbent assay. Additionally, affinity-purified polyclonal anti-cyclic-citrullinated peptide (CCP2) IgG, and monoclonal antibodies derived from RA blood and synovial fluid B cells (n=175), were screened for CPP3-reactivity. Elevated anti-CPP3 antibody levels were detected in RA (11%), mainly CCP2+ RA, compared to controls (2%), p<0.0001, with a significant association to HLA-DRB1 shared epitope alleles, smoking and baseline pain, but with low correlation to autoimmune ACPA fine-specificities. Monoclonal antibodies derived from gingival B cells showed cross-reactivity between P. gingivalis CPP3 and human citrullinated peptides, and a CPP3+/CCP2+ clone, derived from an RA blood memory B cell, was identified. Our data support the possibility that immunity to P. gingivalis derived citrullinated antigens, triggered in the inflamed gum mucosa, may contribute to the presence of ACPA in RA patients, through mechanisms of molecular mimicry. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Exhaled nitric oxide in early rheumatoid arthritis and effects of methotrexate treatment.
- Author
-
Weitoft, Tomas, Lind, Anders, Larsson, Anders, Rönnelid, Johan, and Högman, Marieann
- Subjects
RHEUMATOID arthritis ,NITRIC oxide ,TREATMENT effectiveness ,IMMUNOSUPPRESSION ,BIOMARKERS ,RHEUMATOID factor ,THERAPEUTICS - Abstract
Patients with established rheumatoid arthritis (RA) and disease modifying treatments have lower nitric oxide (NO) levels in the alveolar compartment (C
A NO) and in the airway wall (Caw NO), but also higher diffusion capacities for NO in the airways (Daw NO) compared to matched controls. The aim of the present study was to investigate the NO lung dynamics in patients with recent onset RA before and after immune suppression with methotrexate therapy. Patients with early RA and antibodies against anticitrullinated peptides (ACPA) were recruited. Measurement of exhaled NO and inflammatory markers in serum were performed. Clinical disease activity was evaluated with Disease Activity Score for 28 joints. Healthy individuals were used as matched controls. Data are presented as median (lower quartile, upper quartile) values. RA patients (n = 44) had lower exhaled NO (FE NO50 ) 16 (10–24) ppb compared to controls 21 (15, 29) ppb, p = 0.013. In NO-dynamics, CA NO was lower in RA patients 1.6 (1.0, 2.2) ppb compared to the control subjects 2.3 (1.3, 3.1) ppb, p = 0.007. Caw NO was also lower in the RA patients 55 (24, 106) ppb compared to control subjects 124 (110, 170) ppb, p < 0.001, but Daw NO was higher 17 (8, 30) mL/s and 9 (5, 11) mL/s respectively, p < 0.001. Methotrexate treatment for three months reduced disease activity, but did not change the NO dynamics. In conclusion, the altered NO dynamics of the lung in ACPA-positive RA patients are already present in the early stages of the disease before any treatments and do not change after methotrexate therapy suggesting a role in the pathogenesis. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. Exhaled nitric oxide in early rheumatoid arthritis and effects of methotrexate treatment.
- Author
-
Weitoft, Tomas, Lind, Anders, Larsson, Anders, Rönnelid, Johan, and Högman, Marieann
- Subjects
RHEUMATOID arthritis ,NITRIC oxide ,TREATMENT effectiveness ,IMMUNOSUPPRESSION ,BIOMARKERS ,RHEUMATOID factor ,THERAPEUTICS - Abstract
Patients with established rheumatoid arthritis (RA) and disease modifying treatments have lower nitric oxide (NO) levels in the alveolar compartment (C
A NO) and in the airway wall (Caw NO), but also higher diffusion capacities for NO in the airways (Daw NO) compared to matched controls. The aim of the present study was to investigate the NO lung dynamics in patients with recent onset RA before and after immune suppression with methotrexate therapy. Patients with early RA and antibodies against anticitrullinated peptides (ACPA) were recruited. Measurement of exhaled NO and inflammatory markers in serum were performed. Clinical disease activity was evaluated with Disease Activity Score for 28 joints. Healthy individuals were used as matched controls. Data are presented as median (lower quartile, upper quartile) values. RA patients (n = 44) had lower exhaled NO (FE NO50 ) 16 (10–24) ppb compared to controls 21 (15, 29) ppb, p = 0.013. In NO-dynamics, CA NO was lower in RA patients 1.6 (1.0, 2.2) ppb compared to the control subjects 2.3 (1.3, 3.1) ppb, p = 0.007. Caw NO was also lower in the RA patients 55 (24, 106) ppb compared to control subjects 124 (110, 170) ppb, p < 0.001, but Daw NO was higher 17 (8, 30) mL/s and 9 (5, 11) mL/s respectively, p < 0.001. Methotrexate treatment for three months reduced disease activity, but did not change the NO dynamics. In conclusion, the altered NO dynamics of the lung in ACPA-positive RA patients are already present in the early stages of the disease before any treatments and do not change after methotrexate therapy suggesting a role in the pathogenesis. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
15. The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.
- Author
-
Marklein, Bianka, Jenning, Madeleine, Konthur, Zoltán, Häupl, Thomas, Welzel, Franziska, Nonhoff, Ute, Krobitsch, Sylvia, Mulder, Debbie M., Koenders, Marije I., Joshua, Vijay, Cope, Andrew P., Shlomchik, Mark J., Anders, Hans-Joachim, Burmester, Gerd R., Hensvold, Aase, Catrina, Anca I., Rönnelid, Johan, Steiner, Günter, and Skriner, Karl
- Published
- 2021
- Full Text
- View/download PDF
16. The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.
- Author
-
Marklein, Bianka, Jenning, Madeleine, Konthur, Zoltán, Häupl, Thomas, Welzel, Franziska, Nonhoff, Ute, Krobitsch, Sylvia, Mulder, Debbie M., Koenders, Marije I., Joshua, Vijay, Cope, Andrew P., Shlomchik, Mark J., Anders, Hans-Joachim, Burmester, Gerd R., Hensvold, Aase, Catrina, Anca I., Rönnelid, Johan, Steiner, Günter, and Skriner, Karl
- Published
- 2021
- Full Text
- View/download PDF
17. Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE.
- Author
-
Elbagir, Sahwa, Grosso, Giorgia, Mohammed, NasrEldeen A, Elshafie, Amir I, Elagib, Elnour M, Zickert, Agneta, Manivel, Vivek Anand, Pertsinidou, Eleftheria, Nur, Musa A. M, Gunnarsson, Iva, Rönnelid, Johan, and Svenungsson, Elisabet
- Subjects
PHOSPHOLIPID antibodies ,PROTHROMBIN ,ANTIBODY titer ,THROMBOSIS ,IMMUNOGLOBULINS - Abstract
Objectives: Antiphosphatidylserine/prothrombin complex antibodies (aPS/PT) are risk factors for thrombosis, yet further validation of their clinical relevance in different ethnic groups is required. We investigated the performance of aPS/PT of IgA/G/M isotypes among Sudanese and Swedish systemic lupus erythematosus (SLE) patients. Methods: Consecutive SLE patients/matched controls from Sudan (n = 91/102) and Sweden (n = 332/163) were included. All patients fulfilled the 1982 ACR SLE classification criteria. IgA/G/M of aPS/PT, anti-cardiolipin and anti-β
2 glycoprotein I (anti-β2 GPI) were tested in both cohorts, and lupus anticoagulant (LA) also in the Swedish cohort. Clinical antiphospholipid syndrome-related events and atherosclerosis, measured as carotid plaques were assessed for associations. Univariate and multivariate analyses adjusting for cardiovascular risk factors were performed. Results: Sudanese SLE patients had higher levels of IgM aPS/PT, but using national cut-offs, the frequency of positivity was similar to Swedish patients for all isotypes. Among Swedish patients, all isotypes of aPS/PT associated with venous thromboembolism (VTE), while only IgA aPS/PT associated with arterial thrombosis (AT). aPS/PT antibodies associated strongly with LA and they were, independently, the best predictor for VTE. Double positivity for aPS/PT and anti-β2 GPI associated with higher VTE risk than the conventional triple positivity. Carotid plaques did not associate with any antiphospholipid antibody. Conclusions: IgA aPS/PT associated with AT, and the association of IgG/M aPS/PT with VTE outperforms LA and criteria antiphospholipid antibodies in Swedish SLE patients. Furthermore, double positivity for aPS/PT and anti-β2 GPI performed better than conventional triple positivity. Future studies need to address if aPS/PT can replace LA, as this would simplify clinical procedures. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives.
- Author
-
Rönnelid, Johan, Turesson, Carl, and Kastbom, Alf
- Subjects
AUTOANTIBODIES ,PHYSICIANS ,RHEUMATOID factor ,RHEUMATOID arthritis diagnosis ,LIKELIHOOD ratio tests ,RHEUMATOID arthritis ,AUTOIMMUNE diseases - Abstract
Measurement of two groups of autoantibodies, rheumatoid factor (RF) and anti-citrullinated protein/peptide antibodies (ACPA) have gained increasing significance in the diagnosis and classification of rheumatoid arthritis (RA) over the last 65 years. Despite this rising importance of autoimmune serology in RA, there is a palpable lack of harmonization between different commercial RF and ACPA tests. While a minimal diagnostic specificity has been defined for RF tests, which almost always are related to an international reference preparation, neither of this applies to ACPA. Especially assays with low diagnostic specificity are associated with very low positive predictive values or post-test probabilities in real world settings. In this review we focus on issues of practical bearing for the clinical physician diagnosing patients who potentially have RA, or treating patients diagnosed with RA. We advocate that all clinically used assays for RF and ACPA should be aligned to a common diagnostic specificity of 98-99% compared to healthy controls. This high and rather narrow interval corresponds to the diagnostic specificity seen for many commercial ACPA tests, and represents a specificity that is higher than what is customary for most RF assays. Data on antibody occurrence harmonized in this way should be accompanied by test result-specific likelihood ratios for the target diagnosis RA on an ordinal or interval scale, which will provide the clinical physician with more granular and richer information than merely relating numerical values to a single cut-off point. As many physicians today are used to evaluate autoantibodies as positive or negative on a nominal scale, the introduction of test result-specific likelihood ratios will require a change in clinical mindset. We also discuss the use of autoantibodies to prognosticate future arthritis development in at-risk patients as well as predict severe disease course and outcome of pharmacological treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases.
- Author
-
Kharlamova, Nastya, Dunn, Nicky, Bedri, Sahl K., Jerling, Svante, Almgren, Malin, Faustini, Francesca, Gunnarsson, Iva, Rönnelid, Johan, Pullerits, Rille, Gjertsson, Inger, Lundberg, Karin, Månberg, Anna, Pin, Elisa, Nilsson, Peter, Hober, Sophia, Fink, Katharina, and Fogdell-Hahn, Anna
- Subjects
CHRONICALLY ill ,SERODIAGNOSIS ,SARS-CoV-2 ,IMMUNOSPECIFICITY ,SYSTEMIC lupus erythematosus - Abstract
Patients with chronic inflammatory diseases are often treated with immunosuppressants and therefore are of particular concern during the SARS-CoV-2 pandemic. Serological tests will improve our understanding of the infection and immunity in this population, unless they tests give false positive results. The aim of this study was to evaluate the specificity of SARS-Cov-2 serological assays using samples from patients with chronic inflammatory diseases collected prior to April 2019, thus defined as negative. Samples from patients with multiple sclerosis (MS, n=10), rheumatoid arthritis (RA, n=47) with or without rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibodies (anti-CCP2) and systemic lupus erythematosus (SLE, n=10) with or without RF, were analyzed for SARS-CoV-2 antibodies using 17 commercially available lateral flow assays (LFA), two ELISA kits and one in-house developed IgG multiplex bead-based assay. Six LFA and the in-house validated IgG assay correctly produced negative results for all samples. However, the majority of assays (n=13), gave false positive signal for samples from patients with RA and SLE. This was most notable in samples from RF positive RA patients. No false positive samples were detected in any assay using samples from patients with MS. Poor specificity of commercial serological assays could possibly be, at least partly, due to interfering antibodies in samples from patients with chronic inflammatory diseases. For these patients, the risk of false positivity should be considered when interpreting results of the SARS-CoV-2 serological assays. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Clinical characteristics of Vietnamese patients with idiopathic inflammatory myopathies and autoantibodies to aminoacyl‐transfer RNA synthetases.
- Author
-
Phuong, Thuy Nguyen Thi, Ngoc, Lan Nguyen Thi, Rönnelid, Johan, Padyukov, Leonid, and Lundberg, Ingrid E.
- Subjects
MYOSITIS ,AUTOANTIBODIES ,LIGASES ,RAYNAUD'S disease ,MUSCLE diseases ,MUSCLE weakness - Abstract
Objective: To assess clinical phenotypes of anti‐aminoacyl‐transfer RNA synthetases (aaRS) autoantibodies in Vietnamese patients of Kinh ethnicity with idiopathic inflammatory myopathies (IIM). Methods: In a cross‐sectional study 23 patients with anti‐aaRS autoantibodies were compared to 36 patients with other myositis‐specific antibodies and to 69 seronegative patients with IIM. Assessments included muscle performance, extra‐muscular involvement, and disease activity according to the International Myositis Assessment and Clinical Studies (IMACS). Sera were tested by a line immunoassay (Euroline Myositis Profile 4). Results: The frequency of anti‐Jo‐1 antibodies was 56.5%, anti‐EJ antibodies 26.1%, and anti‐PL‐7 antibodies 17.4%, while anti‐PL‐12 and anti‐OJ antibodies were not present in any case. All patients with anti‐aaRS autoantibodies had signs of myositis. At time of investigation 22/23 patients had muscle weakness, 52.2% arthritis, 34.8% Raynaud's phenomenon, 73.9% fever, 14.3% mechanic's hands and 56.5% dysphagia. Interstitial lung disease was present in 52.2%, and pulmonary hypertension in 56.5%. The anti‐aaRS autoantibody positive group had higher disease activity in the domains of skin and pulmonary disease compared to the seronegative group and had lower disease activity in skeletal disease compared to the anti‐melanoma differentiation‐associated protein 5‐positive patients. The clinical presentation of antisynthetase syndrome was similar between the aaRS autoantibody specificities with the exception of more frequent pulmonary hypertension in anti‐Jo‐1 positive patients. Conclusions: Different aaRS autoantibody specificities may vary between different ethnic populations for reasons that still need to be clarified. Furthermore, the high frequency of pulmonary hypertension is noteworthy but otherwise clinical manifestations associated with aaRS autoantibodies did not differ from other ethnic populations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Harmonization of antineutrophil cytoplasmic antibodies (ANCA) testing by reporting test result-specific likelihood ratios: position paper.
- Author
-
Bossuyt, Xavier, Damoiseaux, Jan, Rasmussen, Niels, van Paassen, Pieter, Hellmich, Bernard, Baslund, Bo, Blockmans, Daniel, Vermeersch, Pieter, Lopez-Hoyos, Marcos, Vercammen, Martine, Barret, Elisa, Hammar, Friederike, Leinfelder, Ulrich, Mahler, Michael, Olschowka, Nina, Roggenbuck, Dirk, Schlumberger, Wolfgang, Walker, Roger, Rönnelid, Johan, and Cohen Tervaert, Jan-Willem
- Subjects
ANTINEUTROPHIL cytoplasmic antibodies ,LIKELIHOOD ratio tests - Abstract
Keywords: antineutrophil cytoplasmic antibodies (ANCA); vasculitis; harmonization; SARS-CoV-2 antibody EN antineutrophil cytoplasmic antibodies (ANCA) vasculitis harmonization SARS-CoV-2 antibody e35 e39 5 01/21/21 20210201 NES 210201 To the Editor, Antineutrophil cytoplasmic antibodies (ANCA) are valuable laboratory markers to support the diagnosis of ANCAassociated vasculitis (AAV). Depending on the assay, 52-66% of AAV patients had a test result with an LR >30 and 14-27% of AAV patients had a test result with an LR between 10 and 30 (Figure 2, Panel B). [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
22. Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis.
- Author
-
Westerlind, Helga, Rönnelid, Johan, Hansson, Monika, Alfredsson, Lars, Mathsson‐Alm, Linda, Serre, Guy, Cornillet, Martin, Holmdahl, Rikard, Jakobsson, Per‐Johan, Skriner, Karl, Klareskog, Lars, Saevarsdottir, Saedis, and Askling, Johan
- Subjects
STROKE risk factors ,CARDIOVASCULAR diseases risk factors ,CONFIDENCE intervals ,IMMUNOGLOBULINS ,LONGITUDINAL method ,RHEUMATOID arthritis ,RISK assessment ,SMOKING ,ECONOMIC status ,PROPORTIONAL hazards models ,SEVERITY of illness index ,ACUTE coronary syndrome ,DESCRIPTIVE statistics ,DISEASE complications - Abstract
Objective: To investigate the relationship between anti–citrullinated protein antibodies (ACPAs), specific ACPA subspecificities, rheumatoid factor (RF) isotypes, and incident cardiovascular (CV) events in patients with rheumatoid arthritis (RA). Methods: Serum samples from Swedish patients with new‐onset RA (diagnosed within 1 year of symptom onset between 1996 and 2009) were centrally typed for anti–cyclic citrullinated peptide 2 (anti‐CCP2) antibodies, 20 ACPA subspecificities, and RF isotypes. Patients were followed up longitudinally in nationwide registers to monitor the occurrence of acute coronary syndrome (ACS), stroke, CV‐related death, and major adverse CV events (MACE). The association between each serologic marker and CV outcome, and the impact of adjustment for the Disease Activity Score in 28 joints (DAS28), smoking status, and income at baseline, were assessed using Cox proportional hazards models. In addition, associations of serologic markers with all‐cause mortality were explored. Results: In total, 2,814 patients with RA were included in the study. The median follow‐up was 13 years, during which the CV end points of ACS, stroke, or CV‐related death were reported to occur in 375 patients. Occurrence and/or levels of anti‐CCP2 were associated with risk of incident ACS (hazard ratio [HR] 1.46, 95% confidence interval [95% CI] 1.03–2.06), stroke (HR 1.47, 95% CI 1.03–2.10), CV‐related death (P = 0.024 for association with anti‐CCP2 levels), and MACE (HR 1.34, 95% CI 1.06–1.70). Similarly, an association with the number of ACPA subspecificities was observed; however, this could not be attributed to any individual or group of ACPA subspecificities. Presence of IgM‐RF was associated with all CV end points except ACS, and IgA‐RF was exclusively associated with CV‐related death. Adjustment for smoking status, income, and DAS28 scores decreased most of the HRs, whereas IgA‐RF remained associated with CV‐related death (HR 1.61, 95% CI 1.05–2.48). All of the assessed serologic makers were associated with all‐cause mortality. Conclusion: RF isotypes and ACPAs are associated with future CV events in patients with RA. ACPA levels and number of subspecificities seem more important than the occurrence of particular subspecificities, and these associations were not explained by a history of ever smoking. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients.
- Author
-
Elbagir, Sahwa, Elshafie, Amir I, Elagib, Elnour M, Mohammed, NasrEldeen A, Aledrissy, Mawahib IE, Manivel, Vivek Anand, Pertsinidou, Eleftheria, Nur, Musa AM, Gunnarsson, Iva, Svenungsson, Elisabet, and Rönnelid, Johan
- Subjects
SYSTEMIC lupus erythematosus ,AUTOANTIBODIES ,PHOSPHOLIPID antibodies ,MEDICAL records - Abstract
Objectives: IgA antiphospholipid antibodies (aPL) are prevalent in systemic lupus erythematosus (SLE) patients of African American, Afro-Caribbean and South African origin. Nevertheless, data from North Africa are lacking, and most studies use manufacturer-suggested cut-offs based on Caucasian controls. Therefore, we compared aPL isotypes in Sudanese and Swedish SLE patients using nation-based cut-offs. Methods: Consecutive SLE patients and age- and sex-matched controls from Sudan (N = 115/106) and Sweden (N = 340/318) were included. All patients fulfilled the 1982 American College of Rheumatology SLE classification criteria. Antiphospholipid syndrome–related events were obtained from patients' records. IgA/G/M anticardiolipin and anti-β
2 glycoprotein I (β2 GPI) were analysed with two independent assays. IgA anti-β2 GPI domain 1 (D1) was also investigated. Manufacturers' cut-offs and the 95th and 99th percentile cut-offs based on national controls were used. Results: Sudanese patients and controls had higher levels and were more often positive for IgA aPL than Swedes when using manufacturers' cut-offs. In contrast, using national cut-offs, the increase in IgA aPL among Sudanese patients was lost. Occurrence of IgA anti-D1 did not differ between the countries. Venous thromboses were less common among Sudanese patients and did not associate with aPL. No clinical associations were observed with IgA anti-β2 GPI in Sudanese patients. Thromboses in Swedes were associated with IgG/M aPL. Fetal loss was associated with aPL in both cohorts. Conclusions: IgA anti-β2 GPI prevalence was higher among Sudanese compared to Swedish patients when manufacturers' cut-offs were used. This situation was reversed when applying national cut-offs. Anti-D1 was not increased in Sudanese patients. Previous studies on populations of African origin, which demonstrate a high prevalence of IgA aPL positivity, should be re-evaluated using a similar cut-off approach. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
24. Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity.
- Author
-
Reed, Evan, Hedström, Anna Karin, Hansson, Monika, Mathsson-Alm, Linda, Brynedal, Boel, Saevarsdottir, Saedis, Cornillet, Martin, Jakobsson, Per-Johan, Holmdahl, Rikard, Skriner, Karl, Serre, Guy, Alfredsson, Lars, Rönnelid, Johan, and Lundberg, Karin
- Published
- 2020
- Full Text
- View/download PDF
25. Sjögren Syndrome in Systemic Lupus Erythematosus: A Subset Characterized by a Systemic Inflammatory State.
- Author
-
Ruacho, Guillermo, Kvarnström, Marika, Zickert, Agneta, Oke, Vilija, Rönnelid, Johan, Eketjäll, Susanna, Elvin, Kerstin, Gunnarsson, Iva, and Svenungsson, Elisabet
- Subjects
SYSTEMIC lupus erythematosus ,AUTOIMMUNE diseases ,ANKYLOSING spondylitis ,CLINICAL trials ,RHEUMATOLOGY - Abstract
Objective: An often-neglected subset of patients with systemic lupus erythematosus (SLE) is those with secondary Sjögren syndrome (SLE-sSS). Further, primary SS overlaps and can be difficult to delineate from SLE. To shed light on the SLE-sSS subset, we investigated a large and well-characterized SLE cohort, comparing patients with SLE-sSS and SLE patients without SS (SLE-nonsSS) and controls.Methods: We included 504 consecutive patients with SLE, fulfilling the 1982 revised American College of Rheumatology criteria, and 319 controls from the general population, matched for age and sex to the first 319 patients. SLE-sSS was defined according to the American-European Consensus Criteria (AECC). A thorough clinical examination, including subjective and objective quantifications of sicca symptoms, was performed in all participants. Autoantibodies and 20 selected cytokines were measured by luminex and multiplex analysis, respectively.Results: SLE-sSS, as defined by AECC, occurred in 23% of the patients with SLE. In comparison to SLE-nonsSS, the SLE-sSS group was older and more frequently female. Leukopenia and peripheral neuropathy were more frequent and nephritis less frequent. Circulating levels of 6/20 investigated proinflammatory cytokines [tumor necrosis factor-α, interleukin (IL) 6, monocyte chemoattractant protein 4, macrophage inflammatory protein 1β, IL-12/IL-23p40, and interferon γ-induced protein 10], total IgG, anti-SSA/Ro52, anti-SSA/Ro60, anti-SSB/La antibodies, and rheumatoid factor (IgM and IgA) were higher in the SLE-sSS group (p < 0.05 for all comparisons).Conclusion: The frequency of SLE-sSS increased with age and affected roughly one-quarter of all patients with SLE. Despite less internal organ involvement, a systemic inflammatory state with high levels of proinflammatory cytokines is present in the SLE-sSS subgroup. This is a novel observation that may affect future understanding and treatment of the SLE-sSS subset. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis.
- Author
-
Tansley, Sarah L., Snowball, Julia, Pauling, John D., Lissina, Anya, Kuwana, Masataka, Rider, Lisa G., Rönnelid, Johan, and McHugh, Neil J.
- Published
- 2020
- Full Text
- View/download PDF
27. The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis.
- Author
-
Klareskog, L., Rönnelid, J., Saevarsdottir, S., Padyukov, L., Alfredsson, L., Klareskog, Lars, Rönnelid, Johan, Saevarsdottir, Saedis, Padyukov, Leonid, and Alfredsson, Lars
- Subjects
RHEUMATOID arthritis ,SYMPTOMS ,IMMUNITY ,SILICA dust ,CIGARETTE smoke ,AIRWAY resistance (Respiration) ,LIFESTYLES ,ARTHRITIS Impact Measurement Scales ,PSYCHOLOGICAL tests ,DISEASE susceptibility ,RESEARCH funding ,PSYCHOLOGICAL adaptation ,PHENOTYPES - Abstract
The current review uses rheumatoid arthritis (RA) as a prominent example for how studies on the interplay between environmental and genetic factors in defined subsets of a disease can be used to formulate aetiological hypotheses that subsequently can be tested for causality using molecular and functional studies. Major discussed findings are that exposures to airways from many different noxious agents including cigarette smoke, silica dust and more interact with major susceptibility genes, mainly HLA-DR genetic variants in triggering antigen-specific immune reactions specific for RA. We also discuss how several other environmental and lifestyle factors, including microbial, neural and metabolic factors, can influence risk for RA in ways that are different in different subsets of RA.The description of these processes in RA provides the best example so far in any immune-mediated disease of how triggering of immunity at one anatomical site in the context of known environmental and genetic factors subsequently can lead to symptoms that precede the classical inflammatory disease symptoms and later contribute also to the classical RA joint inflammation. The findings referred to in the review have led to a change of paradigms for very early therapy and prevention of RA and to efforts towards what we have named 'personalized prevention'. We believe that the progress described here for RA will be of relevance for research and practice also in other immune-mediated diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons.
- Author
-
Elbagir, Sahwa, Elshafie, Amir I, Elagib, Elnour M, Mohammed, NasrEldeen A, Aledrissy, Mawahib I E, Sohrabian, Azita, Nur, Musa A M, Svenungsson, Elisabet, Gunnarsson, Iva, and Rönnelid, Johan
- Subjects
AGE distribution ,AUTOANTIBODIES ,COMPARATIVE studies ,PERIPHERAL neuropathy ,HEALTH outcome assessment ,QUESTIONNAIRES ,SYSTEMIC lupus erythematosus ,DISEASE prevalence ,CASE-control method ,DISEASE duration ,DESCRIPTIVE statistics - Abstract
Objective SLE is known to have an aggressive phenotype in black populations, but data from African cohorts are largely lacking. We therefore compared immunological and clinical profiles between Sudanese and Swedish patients using similar tools. Methods Consecutive SLE patients from Sudan (n = 115) and Sweden (n = 340) and from 106 Sudanese and 318 Swedish age- and sex-matched controls were included. All patients fulfilled the 1982 ACR classification criteria for SLE. Ten ANA-associated specificities and C1q-binding immune complexes (CICs) were measured. Cut-offs were established based on Sudanese and Swedish controls, respectively. Disease activity was measured with a modified SLEDAI and organ damage with the SLICC Damage Index. In a nested case–control design, Swedish and Sudanese patients were matched for age and disease duration. Results Females constituted 95.6% and 88.1% of Sudanese and Swedish patients, respectively (P = 0.02), with younger age at inclusion (33 vs 47.7 years; P < 0.0001) and shorter disease duration (5 vs 14 years; P < 0.0001) among Sudanese patients. Anti-Sm antibodies were more frequent in Sudanese patients, whereas anti-dsDNA, anti-histone and CICs were higher in Swedish patients. In the matched analyses, there was a trend for higher SLEDAI among Swedes. However, Sudanese patients had more damage, solely attributed to high frequencies of cranial/peripheral neuropathy and diabetes. Conclusion While anti-Sm is more common in Sudan than in Sweden, the opposite is found for anti-dsDNA. Sudanese patients had higher damage scores, mainly because of neuropathy and diabetes. Sudanese patients were younger, with a shorter SLE duration, possibly indicating a more severe disease course with impact on survival rates. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation.
- Author
-
Fox, Bernard J., Hockley, Jason, Rigsby, Peter, Dolman, Carl, Meroni, Pier Luigi, and Rönnelid, Johan
- Abstract
Introduction: Antibodies against double-stranded DNA (anti-dsDNA) are a specific biomarker for systemic lupus erythematosus (SLE). The first WHO International Standard (IS) for anti-dsDNA (established in 1985), which was used to assign units to diagnostic tests, was exhausted over a decade ago.Methods: Plasma from a patient with SLE was first evaluated in 42 European laboratories. The plasma was thereafter used by the National Institute for Biological Standards and Control to prepare a candidate WHO reference preparation for lupus (anti-dsDNA) antibodies. That preparation, coded 15/174, was subjected to an international collaborative study, including 36 laboratories from 17 countries.Results: The plasma mainly contained anti-dsDNA, other anti-chromatin antibodies and anti-Ku. The international collaborative study showed that the field would benefit from 15/174 as a common reference reagent improving differences in performance between different assays. However, no statistically meaningful overall potency or assay parallelism and commutability could be shown.Conclusion: 15/174 cannot be considered equivalent to the first IS for anti-dsDNA (Wo/80) and was established as a WHO Reference Reagent for lupus (oligo-specific) anti-dsDNA antibodies with a nominal value of 100 units/ampoule. This preparation is intended to be used to align test methods quantifying levels of anti-dsDNA antibodies. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
30. Establishment of an international autoantibody reference standard for human anti-DFS70 antibodies: proof-of-concept study for a novel Megapool strategy by pooling individual specific sera.
- Author
-
Dellavance, Alessandra, Baldo, Danielle C., Zheng, Bing, Mora, Rodrigo A., Fritzler, Marvin J., Hiepe, Falk, Rönnelid, Johan, Satoh, Minoru, Garcia-De La Torre, Ignacio, Wener, Mark H., Chan, Edward K.L., and Andrade, Luis E.C.
- Subjects
AUTOANTIBODIES ,ENZYME-linked immunosorbent assay ,IMMUNOGLOBULINS ,IMMUNE response ,IMMUNOFLUORESCENCE - Abstract
Background: International autoantibody standards, traditionally based on material obtained from plasmapheresis of single subjects, represent individual immune response and may not comprehend the heterogeneity of the general population. The anti-DFS70 autoantibody yields a characteristic dense fine speckled (DFS) nuclear pattern on indirect immunofluorescence assay on HEp-2 cells (HEp-2 IFA) and speaks against autoimmunity. We propose a novel strategy for developing autoantibody reference standards, based on stepwise pooling of serum samples from hundreds of individuals with anti-DFS70 antibodies. Methods: Within a 2-year period, serum samples were selected from routine HEp-2 IFA according to the following criteria: DFS HEp-2 IFA pattern at titer ≥1:640; anti-DFS70 reactivity in three analyte-specific tests (Western blot [WB], enzyme-linked immunosorbent assay [ELISA] and chemiluminescent immunoassay [CLIA]). Aliquots of individual samples were combined into progressively larger pools with stepwise validation of intermediary pools as for individual samples. Validated intermediary pools were merged into a final pool for lyophilization. Results: A total of 741 validated samples yielded a 750 mL final pool that was lyophilized into thousands of 200 μL-aliquots. Reconstituted aliquots yielded the expected anti-DFS70 reactivity in ELISA, CLIA and WB, as well as high-titer DFS HEp-2 IFA pattern. The appropriate anti-DFS70 reactivity of the lyophilized pool was confirmed by seven international expert centers, using HEp-2 IFA, ELISA, WB and immunoprecipitation. Conclusions: This proof-of-concept study provides an innovative and efficient strategy to build serum reference standards for autoantibody testing. The anti-DFS70 standard will integrate the panel of standards of Autoantibody Standardization Committee (ASC, www.autoab.org), contributing to education for proper assay validation and interpretation of the DFS pattern and other HEp-2 IFA patterns. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. Antibodies against citrullinated peptides are associated with clinical and radiological outcomes in patients with early rheumatoid arthritis: a prospective longitudinal inception cohort study.
- Author
-
Boman, Antonia, Brink, Mikael, Lundquist, Anders, Hansson, Monica, Mathsson-Alm, Linda, Rönnelid, Johan, Berglin, Ewa, Holmdahl, Rikard, Skriner, Karl, Serre, Guy, Klareskog, Lars, and Rantapää-Dahlqvist, Solbritt
- Published
- 2019
- Full Text
- View/download PDF
32. Complex Relationships of Smoking, HLA–DRB1 Genes, and Serologic Profiles in Patients With Early Rheumatoid Arthritis: Update From a Swedish Population‐Based Case–Control Study.
- Author
-
Hedström, Anna Karin, Rönnelid, Johan, Klareskog, Lars, and Alfredsson, Lars
- Subjects
RHEUMATOID arthritis risk factors ,AUTOANTIBODIES ,BLOOD proteins ,CONFIDENCE intervals ,GENES ,SEROLOGY ,SMOKING ,HLA-B27 antigen ,LOGISTIC regression analysis ,CASE-control method ,ODDS ratio ,GENOTYPES - Abstract
Objective: Smoking is associated with an increased risk of rheumatoid arthritis (RA) in subsets of patients defined according to the presence or absence of anti–citrullinated protein antibodies (ACPAs) and rheumatoid factors (RFs). Moreover, an interaction between smoking and the HLA–DRB1 shared epitope (SE) has been demonstrated to be a risk factor for seropositive RA. The aim of this study was to investigate the interplay between smoking and the HLA–DRB1 SE with regard to risk of RA in different patient subsets based on ACPA and RF status. Methods: Incident cases of RA (3,645 cases, 5,883 matched controls) were divided into 4 subgroups based on the presence or absence of RF and anti–cyclic citrullinated peptide 2 (anti‐CCP2) antibodies. The influence of smoking on the risk of disease was determined in each RA subgroup, using logistic regression models with calculation of odds ratios and 95% confidence intervals (95% CIs). The potential interaction between smoking and HLA–DRB1 SE genes was evaluated by calculating the attributable proportion due to interaction (AP). Results: In the RF+/anti‐CCP2+ subset of RA patients, both smoking and the presence of the HLA–DRB1 SE conferred independent disease risks, and there was a strong interaction between the 2 risk factors (AP 0.4, 95% CI 0.3, 0.5). In the RF−/anti‐CCP2+ patient subset, the HLA–DRB1 SE conferred an increased risk of RA, whereas the independent influence of smoking was limited. However, there was a significant interaction between the HLA–DRB1 SE and smoking (AP 0.2, 95% CI 0.02, 0.5). In the RF+/anti‐CCP2− patient subset, there was an increased risk of disease among smokers, which was only marginally affected by the presence of the HLA–DRB1 SE, and no interaction between the 2 factors was observed (AP 0.002, 95% CI −0.3, 0.3). In the RF−/anti‐CCP2− patient subset, neither smoking nor the presence of the HLA–DRB1 SE conferred an increased risk of RA. Conclusion: These findings demonstrate different effects of smoking and HLA–DRB1 in the 4 serologically defined RA subsets. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
33. Occurrence of anti-CCP2 and RF isotypes and their relation to age and disease severity among Sudanese patients with rheumatoid arthritis.
- Author
-
Elshafie, Amir I., Elbagir, Sahwa, Aledrissy, Mawahib I. E., Elagib, Elnour M., Nur, Musa A. M., and Rönnelid, Johan
- Subjects
RHEUMATOID factor ,AGE factors in disease ,ENZYME-linked immunosorbent assay ,RHEUMATOID arthritis ,DEVELOPED countries ,AGE of onset ,AUTOANTIBODIES ,DISEASE duration - Abstract
Objective: Anti-cyclic citrullinated peptide 2 antibodies (anti-CCP2) and rheumatoid factor (RF) in rheumatoid arthritis (RA) has been extensively assessed in industrialized countries. We investigated the diagnostic and prognostic impact of anti-CCP2 and RF isotypes in a Sudanese cross-sectional RA cohort. Methods: Consecutive RA patients (n = 281) diagnosed according to the 1987 ACR criteria were included 2008–2010. Anti-CCP2 and RF isotypes (IgA, IgM, and IgG) were measured by enzyme immunoassay in 262 patients, with reference intervals aligned to the same diagnostic specificity as for anti-CCP2 (97.6%) using national controls. Results: IgA RF was the predominant RA-associated autoantibody (56%), followed by IgM RF and anti-CCP2 (both 52%) and IgG RF (49%). In receiver operator characteristic analysis, IgA RF also showed the largest area under the curve. Patients with IgG RF were younger and had 8 years lower median age of disease onset compared to antibody negative patients (p < 0.0001). IgG RF was the only marker associated with a high number of involved joints (p = 0.028), and together with anti-CCP2 were the strongest markers for finger deformities (p = 0.016 and p = 0.012), respectively. No statistical differences were found for disease duration, ESR and Hb levels, and occurrence of erosions/osteopenia for any of the investigated autoantibodies. Conclusion: Whereas IgA RF showed the best diagnostic performance, IgG RF associated with low age of RA onset, high number of involved joints, and finger deformities. These findings indicate that RA-associated antibodies other than conventional IgM RF and anti-CCP2 might be informative in non-Caucasian RA populations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
34. Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients.
- Author
-
Idborg, Helena, Zandian, Arash, Ossipova, Elena, Wigren, Edvard, Preger, Charlotta, Mobarrez, Fariborz, Checa, Antonio, Sohrabian, Azita, Pucholt, Pascal, Sandling, Johanna K., Fernandes-Cerqueira, Cátia, Rönnelid, Johan, Oke, Vilija, Grosso, Giorgia, Kvarnström, Marika, Larsson, Anders, Wheelock, Craig E., Syvänen, Ann-Christine, Rönnblom, Lars, and Kultima, Kim
- Subjects
INTERFERON regulatory factors ,SYSTEMIC lupus erythematosus ,BIOLOGICAL tags ,IMMUNOGLOBULINS ,PROTEOMICS ,BLOOD proteins ,IMMUNOLOGY - Abstract
Systemic Lupus Erythematosus (SLE) is a heterogeneous autoimmune disease, which currently lacks specific diagnostic biomarkers. The diversity within the patients obstructs clinical trials but may also reflect differences in underlying pathogenesis. Our objective was to obtain protein profiles to identify potential general biomarkers of SLE and to determine molecular subgroups within SLE for patient stratification. Plasma samples from a cross-sectional study of well-characterized SLE patients (n = 379) and matched population controls (n = 316) were analyzed by antibody suspension bead array targeting 281 proteins. To investigate the differences between SLE and controls, Mann–Whitney U -test with Bonferroni correction, generalized linear modeling and receiver operating characteristics (ROC) analysis were performed. K-means clustering was used to identify molecular SLE subgroups. We identified Interferon regulating factor 5 (IRF5), solute carrier family 22 member 2 (SLC22A2) and S100 calcium binding protein A12 (S100A12) as the three proteins with the largest fold change between SLE patients and controls (SLE/Control = 1.4, 1.4, and 1.2 respectively). The lowest p -values comparing SLE patients and controls were obtained for S100A12, Matrix metalloproteinase-1 (MMP1) and SLC22A2 (p
adjusted = 3 × 10−9 , 3 × 10−6 , and 5 × 10−6 respectively). In a set of 15 potential biomarkers differentiating SLE patients and controls, two of the proteins were transcription factors, i.e., IRF5 and SAM pointed domain containing ETS transcription factor (SPDEF). IRF5 was up-regulated while SPDEF was found to be down-regulated in SLE patients. Unsupervised clustering of all investigated proteins identified three molecular subgroups among SLE patients, characterized by (1) high levels of rheumatoid factor-IgM, (2) low IRF5, and (3) high IRF5. IRF5 expressing microparticles were analyzed by flow cytometry in a subset of patients to confirm the presence of IRF5 in plasma and detection of extracellular IRF5 was further confirmed by immunoprecipitation-mass spectrometry (IP-MS). Interestingly IRF5, a known genetic risk factor for SLE, was detected extracellularly and suggested by unsupervised clustering analysis to differentiate between SLE subgroups. Our results imply a set of circulating molecules as markers of possible pathogenic importance in SLE. We believe that these findings could be of relevance for understanding the pathogenesis and diversity of SLE, as well as for selection of patients in clinical trials. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
35. Correspondence on 'Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities'.
- Author
-
Rönnelid, Johan, Dahlström, Örjan, Dahle, Charlotte, and Sjöwall, Christopher
- Published
- 2023
- Full Text
- View/download PDF
36. International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I.
- Author
-
Andrade, Luis E. C., Klotz, Werner, Herold, Manfred, Conrad, Karsten, Rönnelid, Johan, Fritzler, Marvin J., von Mühlen, Carlos A., Satoh, Minoru, Damoiseaux, Jan, de Melo Cruvinel, Wilson, and Chan, Edward K. L.
- Subjects
ANTINUCLEAR factors ,DNA topoisomerase I ,CLASSIFICATION algorithms ,METAPHASE (Mitosis) ,CHROMATIN - Abstract
The indirect immunofluorescence assay (IFA) on HEp-2 cells is the reference method for autoantibody screening. The HEp-2 IFA pattern provides useful information on the possible autoantibodies in the sample. The International Consensus on Antinuclear Antibody Patterns (ICAP) initiative seeks to define and harmonize the nomenclature of HEp-2 IFA patterns. The most relevant and usual patterns have been assigned an alphanumeric code from anti-cell (AC)-1 to AC-28 and were organized into a classification algorithm (www.ANApatterns.org). The systemic sclerosis-associated autoantibodies to DNA topoisomerase I (Topo I) produce a peculiar composite 5-element HEp-2 IFA pattern (Topo I-like pattern) comprising the staining of the nucleus, metaphase chromatin plate, nucleolar organizing region, cytoplasm and nucleolus. In a recent assessment of the European Consensus Finding Study Group on autoantibodies, a well-defined anti-Topo I sample was blindly analyzed and classified according to ICAP AC patterns by 43 participant laboratories across Europe. There were wide variations among these laboratories in reporting nuclear, nucleolar and cytoplasmic patterns, indicating the inadequacy of the existing AC patterns to report the Topo I-like pattern. Several ICAP member laboratories independently demonstrated the overall consistency of the HEp-2 IFA Topo I-like pattern using HEp-2 slides from different manufacturers. The ICAP committee reviewed 24 candidate images and selected the four most representative images to be available on the ICAP website. The proper recognition of the AC-29 pattern should trigger suspicion of the presence of anti-Topo I antibodies, which may engender appropriate analyte-specific reflex tests to confirm the autoantibody specificity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
37. Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis.
- Author
-
Sohrabian, Azita, Mathsson-Alm, Linda, Hansson, Monika, Knight, Ann, Lysholm, Jörgen, Cornillet, Martin, Skriner, Karl, Serre, Guy, Larsson, Anders, Weitoft, Tomas, and Rönnelid, Johan
- Abstract
Introduction: Individual patients with rheumatoid arthritis (RA) show divergent specific anti-citrullinated protein/peptide antibodies (ACPA) patterns, but hitherto no individual ACPA specificity has consistently been linked to RA pathogenesis. ACPA are also implicated in immune complexes (IC)-associated joint pathology, but until now, there has been no method to investigate the role of individual ACPA in RA IC formation and IC-associated pathogenesis.Methods: We have developed a new technique based on IC binding to C1q-coated magnetic beads to purify and solubilise circulating IC in sera and synovial fluids (SF) from 77 patients with RA. This was combined with measurement of 19 individual ACPA in serum, SF and in the IC fractions from serum and SF. We investigated whether occurrence of individual ACPA as well as number of ACPA in these compartments was related to clinical and laboratory measures of disease activity and inflammation.Results: The majority of individual ACPA reactivities were enriched in SF as compared with in serum, and levels of ACPA in IC were regulated independently of levels in serum and SF. No individual ACPA reactivity in any compartment showed a dominating association to clinical and laboratory measures of disease activity and severity. Instead, the number of individual ACPA reactivities in the IC fraction from SF associated with a number of markers of joint destruction and inflammation.Conclusions: Our data highlight the polyclonality of ACPA in joint IC and the possibility that a broad ACPA repertoire in synovial fluid IC might drive the local inflammatory and matrix-degrading processes in joints, in analogy with antibody-induced rodent arthritis models. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
38. Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants.
- Author
-
Rönnelid, Johan, Hansson, Monika, Mathsson-Alm, Linda, Cornillet, Martin, Reed, Evan, Jakobsson, Per-Johan, Alfredsson, Lars, Holmdahl, Rikard, Skriner, Karl, Serre, Guy, Lundberg, Karin, and Klareskog, Lars
- Subjects
ALLELES ,ARGININE ,COMPARATIVE studies ,DISEASE susceptibility ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,RHEUMATOID arthritis ,SMOKING ,HLA-B27 antigen ,EVALUATION research ,CASE-control method ,PROTEIN microarrays ,GENOTYPES - Abstract
Introduction: The second generation anticycliccitrullinated peptide (anti-CCP2) assay detects the majority but not all anticitrullinated protein/peptide antibodies (ACPA). Anti-CCP2-positive rheumatoid arthritis (RA) is associated with HLA-DRB1* shared epitope (SE) alleles and smoking. Using a multiplex assay to detect multiple specific ACPA, we have investigated the fine specificity of individual ACPA responses and the biological impact of additional ACPA reactivity among anti-CCP2-negative patients.Methods: We investigated 2825 patients with RA and 551 healthy controls with full data on anti-CCP2, HLA-DRB1* alleles and smoking history concerning reactivity against 16 citrullinated peptides and arginine control peptides with a multiplex array.Results: The prevalence of the 16 ACPA specificities ranged from 9% to 58%. When reactivity to arginine peptides was subtracted, the mean diagnostic sensitivity increased by 3.2% with maintained 98% specificity. Of the anti-CCP2-negative patients, 16% were found to be ACPA positive. All ACPA specificities associated with SE, and all but one with smoking. Correction for arginine reactivity also conveyed a stronger association with SE for 13/16 peptides. Importantly, when all ACPA specificities were analysed together, SE and smoking associated with RA in synergy among ACPA positive, but not among ACPA-negative subjects also in the anti-CCP2-negative subset.Conclusions: Multiplexing detects an enlarged group of ACPA-positive but anti-CCP2-negative patients with genetic and environmental attributes previously assigned to anti-CCP2-positive patients. The individual correction for arginine peptide reactivity confers both higher diagnostic sensitivity and stronger association to SE than gross ACPA measurement. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
39. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.
- Author
-
Tjärnlund, Anna, Quan Tang, Wick, Cecilia, Dastmalchi, Maryam, Mann, Herman, Studýnková, Jana Tomasová, Chura, Radka, Gullick, Nicola J., Salerno, Rosaria, Rönnelid, Johan, Alexanderson, Helene, Lindroos, Eva, Aggarwal, Rohit, Gordon, Patrick, Vencovsky, Jiri, Lundberg, Ingrid E., Tang, Quan, and Tomasová Studýnková, Jana
- Subjects
COMPARATIVE studies ,DERMATOMYOSITIS ,DRUG administration ,IMMUNOSUPPRESSIVE agents ,RESEARCH methodology ,MEDICAL cooperation ,POLYMYOSITIS ,RESEARCH ,PILOT projects ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness - Abstract
Objectives: To study the effects of abatacept on disease activity and on muscle biopsy features of adult patients with dermatomyositis (DM) or polymyositis (PM).Methods: Twenty patients with DM (n=9) or PM (n=11) with refractory disease were enrolled in a randomised treatment delayed-start trial to receive either immediate active treatment with intravenous abatacept or a 3 month delayed-start. The primary endpoint was number of responders, defined by the International Myositis Assessment and Clinical Studies Group definition of improvement (DOI), after 6 months of treatment. Secondary endpoints included number of responders in the early treatment arm compared with the delayed treatment arm at 3 months. Repeated muscle biopsies were investigated for cellular markers and cytokines.Results: 8/19 patients included in the analyses achieved the DOI at 6 months. At 3 months of study, five (50%) patients were responders after active treatment but only one (11%) patient in the delayed treatment arm. Eight adverse events (AEs) were regarded as related to the drug, four mild and four moderate, and three serious AEs, none related to the drug. There was a significant increase in regulatory T cells (Tregs), whereas other markers were unchanged in repeated muscle biopsies.Conclusions: In this pilot study, treatment of patients with DM and PM with abatacept resulted in lower disease activity in nearly half of the patients. In patients with repeat muscle biopsies, an increased frequency of Foxp3+ Tregs suggests a positive effect of treatment in muscle tissue. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
40. The genetically determined production of the alarmin eosinophil-derived neurotoxin is reduced in visceral leishmaniasis.
- Author
-
Blom, Kristin, Elshafie, Amir I., Jönsson, Ulla‐Britt, Rönnelid, Johan, Håkansson, Lena Douhan, and Venge, Per
- Subjects
VISCERAL leishmaniasis ,NEUROTOXIC agents ,EOSINOPHILS ,DENDRITIC cells ,GENETIC polymorphisms ,THERAPEUTICS - Abstract
Visceral leishmaniasis ( VL) is the most severe form of leishmaniasis. Recent findings indicate that dendritic cells have a key role in the defense against the Leishmania parasite and that the activity of this cell may be modified by the eosinophil secretory protein eosinophil-derived neurotoxin ( EDN). We hypothesized that the interactions between dendritic cells and EDN might be of importance in the disease development. Cellular content of EDN was analyzed by ELISA. The single-nucleotide polymorphisms at positions 405, 416, and 1122 in the EDN gene were analyzed by real-time PCR with TaqMan
® reagents. The study cohorts comprised 239 Sudanese subjects (65 healthy controls and 174 with VL) and 300 healthy Swedish controls. The eosinophil content of EDN was lower in VL as compared with controls (p < 0.0001). The EDN405 (G>C) genotype distribution was similar among Swedish and Sudanese controls, whereas VL subjects had a higher prevalence of the EDN405- GG genotype (p < 0.0001). The content of EDN in the eosinophils was closely linked to the EDN405 polymorphism (p = 0.0002). Our findings suggest that the predisposition to acquire VL is related to the genetic polymorphism of the EDN gene and the reduced production by the eosinophil of this gene product. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
41. Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up.
- Author
-
Manivel, Vivek Anand, Mullazehi, Mohammed, Padyukov, Leonid, Westerlind, Helga, Klareskog, Lars, Alfredsson, Lars, Saevarsdottir, Saedis, and Rönnelid, Johan
- Abstract
Objective: Antifibrillar collagen type II (anti-CII) antibody-positive patients with rheumatoid arthritis (RA) have early but not late signs of increased inflammation and joint erosions. We wanted to replicate this in a large RA cohort, and to relate to human leukocyte antigen (HLA)-DRB1* alleles.Methods: Anti-CII and anti-cyclic citrullinated peptide (CCP)2 were measured at baseline in 773 patients with RA from the Swedish Epidemiological Investigation in Rheumatoid Arthritis (EIRA) study with clinical follow-up data from the Swedish Rheumatology Quality Register (SRQ) registry, and 1476 with HLA-DRB1* information. Comparisons were done concerning C reactive protein (CRP), erythrocyte sedimentation rate (ESR), tender joint count (TJC), swollen joint count (SJC), Disease Activity Score encompassing 28 joints based on ESR (DAS28), DAS28CRP, pain-Visual Analogue Scale (VAS), global-VAS and Health Assessment Questionnaire Score (HAQ) at eight occasions during 5 years, and association with HLA-DRB1* alleles.Results: Anti-CII associated with elevated CRP, ESR, SJC, DAS28 and DAS28CRP at diagnosis and up to 6 months, whereas anti-CCP2 associated with SJC and DAS28 from 6 months to 5 years, but not earlier. The anti-CII-associated phenotype was strong, and predominated in anti-CII/anti-CCP2 double-positive patients. Anti-CII was associated with improvements in CRP, ESR, SJC, TJC and DAS28, whereas anti-CCP2 was associated with deteriorations in SJC and DAS28 over time. Anti-CII-positive patients achieved European League Against Rheumatism good or moderate response more often than negative patients. Anti-CII was positively associated with HLA-DRB1*01 and HLA-DRB1*03, with significant interaction, and double-positive individuals had >14 times higher mean anti-CII levels than HLA double negatives. Whereas smoking was associated with elevated anti-CCP2 levels, smokers had lower anti-CII levels.Conclusions: Anti-CII seropositive RA represents a distinct phenotype, in many respects representing the converse to the clinical, genetic and smoking associations described for anticitrullinated protein peptide autoantibodies. Although not diagnostically useful, early anti-CII determinations predict favourable inflammatory outcome in RA. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
42. Differences in the Spectrum of Anti-Citrullinated Protein Antibody Fine Specificities Between Malaysian and Swedish Patients With Rheumatoid Arthritis: Implications for Disease Pathogenesis.
- Author
-
Too, Chun Lai, Murad, Shahnaz, Hansson, Monika, Alm, Linda Mathsson, Dhaliwal, Jasbir Singh, Holmdahl, Rikard, Jakobsson, Per‐Johan, Alfredsson, Lars, Klareskog, Lars, Rönnelid, Johan, and Padyukov, Leonid
- Subjects
AMINO acids ,AUTOANTIBODIES ,BIOLOGICAL assay ,CHI-squared test ,COLLAGEN ,COMPARATIVE studies ,CONFIDENCE intervals ,CYTOSKELETAL proteins ,ENZYMES ,FIBRINOGEN ,MEDICAL cooperation ,PEPTIDES ,PROBABILITY theory ,PROTEINS ,RESEARCH ,RESEARCH funding ,RHEUMATOID arthritis ,STATISTICS ,DATA analysis ,CASE-control method ,RECEIVER operating characteristic curves ,DATA analysis software ,MICROARRAY technology ,DESCRIPTIVE statistics ,ODDS ratio ,GENOTYPES - Abstract
Objective Antibodies to the citrullinated protein antigens (ACPAs) are important in the diagnosis and pathogenesis of rheumatoid arthritis (RA). However, the prevalence of ACPAs with different fine specificities in different populations is unclear. This study sought to examine the fine specificity of the antibody responses toward citrullinated proteins in RA patients from Malaysia, an area where genetic and environmental determinants of RA are different from those in more frequently studied cohorts of Caucasian subjects. Methods A multiplex analytic microarray system was used to analyze the occurrence of antibodies to 10 different citrullinated peptides (filaggrin [fil307-324], vimentin [Vim2-17, Vim60-75], fibrinogen [Fibα563-583, Fibα580-600, Fibβ36-52, Fibβ62-81a, Fibβ62-81b], enolase [Eno5-21], and type II collagen [CitCII355-378]) in serum samples from 4,089 RA patients (1,231 Malaysian and 2,858 Swedish) and 827 healthy control subjects (249 Malaysian and 578 Swedish). The positive reaction threshold for each peptide was set separately for each population based on a specificity of 98%. Results Distinct differences in the frequencies of 5 ACPA fine specificities (Vim60-75, Vim2-17, Fibβ62-81b, Eno5-21, and CitCII355-378) were found between the Malaysian and Swedish RA populations, despite a nearly identical percentage of patients in each population who were positive for anti-cyclic citrullinated peptide 2 antibodies. In Malaysian RA patients compared with Swedish RA patients, the frequencies of antibodies to Vim60-75 (54% versus 44%, corrected P [ P
corr ] = 1.06 × 10−8 ) and CitCII355-378 (17% versus 13%, Pcorr = 0.02) were significantly higher, while the frequencies of antibodies to Vim2-17 (25% versus 32%, Pcorr = 1.91 × 10−4 ), Fibβ62-81b (15% versus 30%, Pcorr = 2.47 × 10−22 ), and Eno5-21 (23% versus 50%, Pcorr = 3.64 × 10−57 ) were significantly lower. Conclusion Serum ACPA fine specificities differ between RA patients in different populations, although the total proportions of individuals positive for ACPAs are similar. Differing patterns of ACPA fine specificity could be attributed to variations in genetic and/or environmental factors. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
43. Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells.
- Author
-
Joshua, Vijay, Schobers, Loes, Titcombe, Philip J., Israelsson, Lena, Rönnelid, Johan, Hansson, Monika, Catrina, Anca I., Pruijn, Ger J. M., and Malmström, Vivianne
- Published
- 2016
- Full Text
- View/download PDF
44. Granulocyte-augmented chemokine production induced by type II collagen containing immune complexes is mediated via TLR4 in rheumatoid arthritis patients.
- Author
-
Manivel, Vivek Anand, Sohrabian, Azita, and Rönnelid, Johan
- Abstract
Rheumatoid arthritis (RA) patients with early elevations of antibodies against collagen type II (CII) have a distinct acute onset phenotype, associated with cytokine induction by surface-bound anti-CII-containing immune complexes (ICs) and high C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Polymorphonuclear granulocytes (PMNs) and peripheral blood mononuclear cells (PBMCs) are abundant in the vicinity of CII in RA joints, and both PMN and PBMC reactivity against anti-CII IC individually relate to early joint destruction and early elevation of CRP and ESR in RA. We searched for CII-dependent mechanisms that might attract PMNs and PBMCs to RA joints. Human PBMCs and PMNs were stimulated with anti-CII ICs and control ICs, either individually or in cocultures. Cocultured PMNs and PBMCs stimulated with anti-CII ICs synergistically augmented production of the chemokines CXCL8, RANTES and MCP-1, whereas downregulation was seen with control IC. This upregulation was unique to chemokines, as TNF-α, IL-1β, and GM-CSF were downregulated in anti-CII IC-stimulated cocultures. The coculture-associated chemokine upregulation depended on endogenous TLR4 ligand(s) and functionally active PMN enzymes, and was partially mediated by GM-CSF. As anti-CII levels peak around the time of RA diagnosis, this mechanism can attract inflammatory cells to joints in early RA and intensify the anti-CII-associated acute onset RA phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
45. Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted α-Enolase T Cell Epitope in Rheumatoid Arthritis.
- Author
-
Gerstner, Christina, Dubnovitsky, Anatoly, Sandin, Charlotta, Kozhukh, Genadiy, Uchtenhagen, Hannes, James, Eddie A., Rönnelid, Johan, Ytterberg, Anders Jimmy, Pieper, Jennifer, Reed, Evan, Tandre, Carolina, Rieck, Mary, Zubarev, Roman A., Rönnblom, Lars, Sandalova, Tatyana, Buckner, Jane H., Achour, Adnane, and Malmström, Vivianne
- Subjects
HLA histocompatibility antigens ,GENETICS of rheumatoid arthritis ,ALLELES - Abstract
Antibodies to citrullinated proteins, common in rheumatoid arthritis (RA) patients, are strongly associated to a specific set of HLA-DR alleles including HLA-DRB1*04:01, *04:04, and *01:01. Here, we first demonstrate that autoantibody levels toward the dominant citrullinated B cell epitope from α-enolase are significantly elevated in HLA-DRB1*04:01-positive RA patients. Furthermore, we identified α-enolase-derived T cell epitopes and demonstrated that native and citrullinated versions of several peptides bind with different affinities to HLA-DRB1*04:01, *04:04, and *01:01. The citrulline residues in the eight identified peptides are distributed throughout the entire length of the presented epitopes and more specifically, localized at peptide positions p-2, p2, p4, p6, p7, p10, and p11. Importantly, in contrast to its native version peptide 26 (TSKGLFRAAVPSGAS), the HLA-DRB1*04:01-restricted citrullinated peptide Cit26 (TSKGLFCitAAVPSGAS) elicited significant functional T cell responses in primary cells from RA patients. Comparative analysis of the crystal structures of HLA-DRB1*04:01 in complex with peptide 26 or Cit26 demonstrated that the posttranslational modification did not alter the conformation of the peptide. And since citrullination is the only structural difference between the two complexes, this indicates that the neo-antigen Cit26 is recognized by T cells with high specificity to the citrulline residue. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies.
- Author
-
Espinosa-Ortega, Fabricio, Holmqvist, Marie, Alexanderson, Helene, Storfors, Helena, Tsuneyo Mimori, Lundberg, Ingrid E., Rönnelid, Johan, and Mimori, Tsuneyo
- Published
- 2019
- Full Text
- View/download PDF
47. Clinical phenotype, autoantibody profile and HLA-DR-type in Vietnamese patients with idiopathic inflammatory myopathies.
- Author
-
Phuong, Thuy Nguyen Thi, Ngoc, Lan Nguyen Thi, Xuan, Hien Nguyen, Rönnelid, Johan, Padyukov, Leonid, and Lundberg, Ingrid E
- Subjects
AUTOANTIBODY analysis ,DERMATOMYOSITIS ,POLYMYOSITIS ,ETHNIC groups ,MYOSITIS ,INTERSTITIAL lung diseases ,PERICARDITIS ,PULMONARY hypertension ,VIETNAMESE people ,HLA-B27 antigen ,PHENOTYPES ,SYMPTOMS ,CROSS-sectional method ,DISEASE duration ,MUSCLE weakness ,GENETICS ,DISEASE risk factors - Published
- 2019
- Full Text
- View/download PDF
48. Active Rheumatoid Arthritis in Central Africa: A Comparative Study Between Sudan and Sweden.
- Author
-
Elshafie, Amir I., Elkhalifa, Abdalla D., Elbagir, Sahwa, Aledrissy, Mawahib I. E., Elagib, Elnour M., Nur, Musa A. M., Weitoft, Tomas, and Rönnelid, Johan
- Published
- 2016
- Full Text
- View/download PDF
49. Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies.
- Author
-
Reed, Evan, Xia Jiang, Kharlamova, Nastya, Ytterberg, A. Jimmy, Catrina, Anca I., Israelsson, Lena, Mathsson-Alm, Linda, Hansson, Monika, Alfredsson, Lars, Rönnelid, Johan, and Lundberg, Karin
- Published
- 2016
- Full Text
- View/download PDF
50. Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis.
- Author
-
Brink, Mikael, Hansson, Monika, Mathsson-Alm, Linda, Wijayatunga, Priyantha, Verheul, Marije K., Trouw, Leendert A., Holmdahl, Rikard, Rönnelid, Johan, Klareskog, Lars, and Rantapää-Dahlqvist, Solbritt
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.